A phase II, multicentre trial of decitabine in higher-risk chronic myelomonocytic leukemia. - Wikidata - wikimedia - TriplyDB

A phase II, multicentre trial of decitabine in higher-risk chronic myelomonocytic leukemia.

A phase II, multicentre trial of decitabine in higher-risk chronic myelomonocytic leukemia.

http://www.wikidata.org/entity/Q33442672

about

A phase I study of lenalidomide in patients with chronic myelomonocytic leukemia (CMML) - AGMT_CMML-1.Prognostic Role of Gene Mutations in Chronic Myelomonocytic Leukemia Patients Treated With Hypomethylating Agents.

P2860

Q38602492-75A41146-F981-4074-9065-EF783FBF1C2A Q55363317-ED93A93B-FEC5-414D-925B-F5B911CBBF06

P2860

A phase II, multicentre trial of decitabine in higher-risk chronic myelomonocytic leukemia.

http://www.wikidata.org/entity/Q33442672

description

2017 nî lūn-bûn

@nan

2017 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2017 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

name

A phase II, multicentre trial ...... ronic myelomonocytic leukemia.

@ast

A phase II, multicentre trial ...... ronic myelomonocytic leukemia.

@en

type

label

A phase II, multicentre trial ...... ronic myelomonocytic leukemia.

@ast

A phase II, multicentre trial ...... ronic myelomonocytic leukemia.

@en

prefLabel

A phase II, multicentre trial ...... ronic myelomonocytic leukemia.

@ast

A phase II, multicentre trial ...... ronic myelomonocytic leukemia.

@en

P1433

Q33442672-4046ECB0-7F0D-4E80-B4B8-6FB2EC313BAF

P1476

Q33442672-2F5E8780-0766-41B3-A529-82326A2DB4A9

P2093

Q33442672-0BAA29D6-7B97-482F-A2B6-FDCA1D174EBC

Q33442672-1F706C5C-BE5A-4DDD-A724-D856AAF81C1C

Q33442672-25BF3CA4-45E8-4B3C-9D8F-6A2191838769

Q33442672-26A36BEB-620E-4FE2-96CE-1CD6057CB4CD

Q33442672-28D8757C-BAC7-487D-9E71-EA24E8A1BAF0

Q33442672-36EA8762-A501-4350-8C77-7D841B4BBC40

Q33442672-3A736F59-ADDD-4034-B859-A74694A20F1D

Q33442672-49252FDB-D46E-45DB-B4E6-0B153B7C44E3

Q33442672-528596FF-A5E8-4F8E-9F4B-B61489002E1E

Q33442672-6DE9D988-D6FC-4D7F-81F4-68FAFFA5151A

P2860

Q33442672-0577439D-F90E-4FFD-84E4-48FFB1938504

Q33442672-161DD89D-F2D4-4276-9C50-7747357B7E56

Q33442672-1DBBB520-24EC-422C-BD6A-CBD2F7FE921E

Q33442672-3ECDB2F8-4F7F-41E7-A655-C375F704C372

Q33442672-43769FB0-49B3-49F8-9066-A1CBAE5717BC

Q33442672-44FE7235-A38D-4A77-86E6-7D104AC0B82A

Q33442672-54948965-8447-4E5F-B0AE-0B1C341E7B77

Q33442672-559DE866-164D-4C6F-8BB4-7B78024639C1

Q33442672-6BDB05FD-91C6-4FC6-8051-E9F2CFF87597

Q33442672-6BE09463-967B-48A7-A0B6-23C600223793

P2888

Q33442672-7CE74DA9-F306-4396-AAC5-3B54E16EF51A

P304

Q33442672-79F096C0-5C3E-42D4-A86F-5F8149BECCCF

P31

Q33442672-57E34E40-772D-4398-B85E-0E77E6C85E14

P356

Q33442672-A5888DA7-FF4E-4B9D-9500-DB7AFEFA8086

P433

Q33442672-D8153766-E356-495E-AF1F-79EDFE59D4FE

P478

Q33442672-711EE046-F7DE-4879-9402-DFB04176B326

P50

Q33442672-A1943582-13DB-47B4-B74C-6A62923188FC

Q33442672-BB382ED1-7AA0-481A-9DBC-AFD3C9BC81DA

Q33442672-ED86FF15-8581-49F7-B6C6-B0BCA8F0372C

P577

Q33442672-D1B3CDD1-1097-424C-894E-14BF21EBBA74

P6179

Q33442672-3862644C-EB48-439B-9742-D15716A134D0

P698

Q33442672-300CD337-8C5B-4122-820B-125DFD7BBB5E

P921

Q33442672-96A89252-9779-4512-8D6F-38EE0CAB7D9E

Q33442672-E367A2EE-CCF6-4322-967D-B52BC16A47E3

P932

Q33442672-A35BD476-BBD5-4D8B-9D17-5D80C8B3F4CE

P356

P1433

P1476

A phase II, multicentre trial ...... ronic myelomonocytic leukemia.

@en

P2093

A Levis

http://www.w3.org/2001/XMLSchema#string

A Pelizzari

http://www.w3.org/2001/XMLSchema#string

A Poloni

http://www.w3.org/2001/XMLSchema#string

A Sanna

http://www.w3.org/2001/XMLSchema#string

A Terenzi

http://www.w3.org/2001/XMLSchema#string

B Allione

http://www.w3.org/2001/XMLSchema#string

C Finelli

http://www.w3.org/2001/XMLSchema#string

D Cilloni

http://www.w3.org/2001/XMLSchema#string

D Ferrero

http://www.w3.org/2001/XMLSchema#string

D Gioia

http://www.w3.org/2001/XMLSchema#string

P2860

Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study

The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia.

Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study

International scoring system for evaluating prognosis in myelodysplastic syndromes

A framework for variation discovery and genotyping using next-generation DNA sequencing data

Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B.

TET2 mutations predict response to hypomethylating agents in myelodysplastic syndrome patients

Activity of decitabine, a hypomethylating agent, in chronic myelomonocytic leukemia.

Cytogenetic risk stratification in chronic myelomonocytic leukemia.

Revised international prognostic scoring system for myelodysplastic syndromes.

P2888

P304

413-418

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/LEU.2017.186

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

32

http://www.w3.org/2001/XMLSchema#string

P50

Emanuele Angelucci

Maria E Figueroa

P577

2017-06-13T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1085998914

http://www.w3.org/2001/XMLSchema#string

P698

28607470

http://www.w3.org/2001/XMLSchema#string

P921

phase II clinical trial

multicenter trial

P932

5808077

http://www.w3.org/2001/XMLSchema#string